Near Term Clinical Applications
The following summarizes additional therapeutic areas where we are currently focusing efforts.

Migraine
Parkinson's disease


Migraine (5-HT1D/1B receptor agonists)  Back to top Top
Background / Market
Many migraine sufferers report they cannot work or function during attacks, while others feel extremely ill or depressed. Migraine requires rapid onset of medication and often a second dose to treat reoccurrence. An estimated 23 million people in the U.S. suffer severe migraine headaches.

Current Therapy
A class of compounds known as "triptans" are the gold standard of treatment, yet their profile needs to be improved. Taken orally they often fail to deliver sufficient quantities of medication in the short time frame required and they provide no protection against the second episode (known as "recurrence") that many migraine patients suffer within 12 to 18 hours after a first attack.

Benefits of Vyteris Iontophoresis
Our controller can be pre-programmed for rapid onset delivery of a bolus dose, to combat the initial onset, followed by a steady low-level maintenance dose, to combat recurrence. This is accomplished automatically in a non-invasive, easy to use product. We know of no other product in the market or under development with this dual capability. This profile of delivery represents a unique and significantly improved therapy and is believed to be the most effective way of preventing recurrence.

Parkinson's disease Back to topTop
Background / Market
Parkinson's disease is a progressively debilitating illness, which breaks down areas of the brain thought to control the coordination of body movements. As many as 1.5 million Americans are currently afflicted with Parkinson's.

Current Therapy
Parkinson's is generally treated with dopamine or dopamine agonist, either alone or in combination. The disadvantages and side effects associated with the oral delivery of dopamine agonists (50% of patients experience nausea and 33% experience hallucination/confusion) can be reduced with our technology.

Benefits of Vyteris Iontophoresis

The benefits of iontophoretic delivery are:
  • Bypassing the GI tract could reduce the incidence of nausea
  • Stable plasma concentration could reduce the incidence of hallucination and nightmare
  • Once a day patch improves patient convenience and compliance vs. orally dosing three times per day
  • Flexibility and control of dosing may ease the burden of titration
  • Potential to avoid on/off phenomenon associated with tremors
 
Home Company Technology Products Partnering Careers News
 
© 2003 Vyteris. All Rights Reserved.